388 related articles for article (PubMed ID: 32533433)
21. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
[TBL] [Abstract][Full Text] [Related]
23. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
24. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
25. Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
Amrhein J; Drynda S; Schlatt L; Karst U; Lohmann CH; Ciarimboli G; Bertrand J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927842
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection.
Faquetti ML; Grisoni F; Schneider P; Schneider G; Burden AM
Sci Rep; 2022 May; 12(1):7843. PubMed ID: 35551258
[TBL] [Abstract][Full Text] [Related]
27. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
28. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice.
González-Freire L; Giménez-Candela RM; Castro-Luaces S; Veiga-Villaverde AB; Crespo-Diz C
Farm Hosp; 2021 Jun; 45(4):165-169. PubMed ID: 34218760
[TBL] [Abstract][Full Text] [Related]
29. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
Scheepers L; Yang Y; Chen YL; Jones G
Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
[TBL] [Abstract][Full Text] [Related]
30. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
31. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
Hoisnard L; Lebrun-Vignes B; Maury S; Mahevas M; El Karoui K; Roy L; Zarour A; Michel M; Cohen JL; Amiot A; Claudepierre P; Wolkenstein P; Grimbert P; Sbidian E
Sci Rep; 2022 May; 12(1):7140. PubMed ID: 35504889
[TBL] [Abstract][Full Text] [Related]
32. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Barbulescu A; Askling J; Chatzidionysiou K; Forsblad-d'Elia H; Kastbom A; Lindström U; Turesson C; Frisell T
Rheumatology (Oxford); 2022 Oct; 61(10):3952-3962. PubMed ID: 35134119
[TBL] [Abstract][Full Text] [Related]
34. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
36. [JAK Inhibitors in Rheumatology].
Witte T
Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
[TBL] [Abstract][Full Text] [Related]
37. Symptomatic elevation creatine kinase following treatment of rheumatoid arthritis with baricitinib.
Anjara P; Jiang M; Mundae M
Clin Rheumatol; 2020 Feb; 39(2):613-614. PubMed ID: 31782014
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
39. Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Dasic G; Jones T; Frajzyngier V; Rojo R; Madsen A; Valdez H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417755
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System.
Liu T; Gao R; Li L; Wu B; Wu F
Int J Clin Pharm; 2023 Dec; 45(6):1483-1491. PubMed ID: 37606843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]